Mandate

Vinge has advised Lendify in connection with a Swedish securitisation

May 22, 2017 Banking and Finance

Lendify AB (”Lendify”), a P2P-lending platform, has issued SEK 200,000,000 bonds on 30 May 2017 through its wholly-owned subsidiary Lendify Sweden 1 AB (publ).

The bonds have a tenor of three years and an annual interest rate of three-months Stibor + 5 %. The bonds are intended to be listed on the regulated market NDX, operated by Nordic Growth Market AB.

The bonds are backed by a portfolio of promissory notes issued by consumers in Sweden in favour of Lendify. The payment of interest and repayment of principal on the bonds are based on the cashflow from the portfolio. The entire documentation is governed by Swedish law and the collateral is held by Intertrust (Sweden) AB, who is also acting as agent for the bondholders.

Together with the management of the company, Carnegie Investment Bank AB (publ) as arranger and issuing agent and its legal advisors, Vinge acted for Lendify in the structuring and documentation of the transaction. Vinge’s team consisted of Jonas Johansson, Emma Stuart-Beck, Albert Wållgren, Louise Nordkvist and André Isacson.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024